Glycovirology is a novel glycan-based platform technology. The concept behind it is that carbohydrate drugs can be used as entry inhibitors that attach directly to the binding domain of different viruses. Our main drug candidate is designed to target the virus instead of the cell like most of the other compounds in development. There is also evidence that carbohydrate drugs are capable of modulating the immune system.
Bioxytran is developing an innovative platform of oxygen therapeutic treatments for hypoxic conditions and necrosis prevention. Our initial targeted medical conditions are brain stroke, wound healing, and trauma. Most of these disease indications can use hyperbaric treatment, but it is costly and limited. In these indications hyperbaric treatment shows promise, but the duration of treatment is limited due to oxygen toxicity our oxygen transport molecule has the ability to impact the duration of treatment due to its drug design.
Bioxytran is developing two platform technologies in the fields of Glycovirology and Hypoxia and Degenerative Diseases. Learn more about our ProLectin & BXT pipelines here.
